Dihydroergotaminedosage

The solution used in dihydroergotamine mesylate nasal spray (4 mg/mL) is intended for intranasal use and must not be injected. In clinical trials, dihydroergotamine mesylate nasal spray has been effective for the acute treatment of migraine headaches with or without aura. One spray (0.5 mg) of dihydroergotamine mesylate nasal spray should be administered in each nostril. Fifteen minutes later, an additional one spray (0.5 mg) of dihydroergotamine mesylate nasal spray should be administered in each nostril, for a total dosage of four sprays (2 mg) of dihydroergotamine mesylate nasal spray. Studies have shown no additional benefit from acute doses greater than 2 mg for a single migraine administration. The safety of doses greater than 3 mg in a 24 hour period and 4 mg in a 7 day period has not been established. Dihydroergotamine mesylate nasal spray, should not be used for chronic daily administration. Prior to administration, the pump must be primed (i.e., squeeze 4 times) before use (see administration instructions). Once the nasal spray applicator has been prepared, it should be discarded (with any remaining drug in opened vial) after 8 hours. Prior to administration, the pump must be primed (i.e., squeeze 4 times) before use (See administration instructions). Once the nasal spray applicator has been prepared, it should be discarded (with any remaining drug in opened vial after 8 hours).